Day 2 :
Rangsit University, Thailand
Time : 10.15 - 11.00
Tirasak Pasharawipas has completed his PhD from Mahidol University in Bangkok, Thailand and Post-doctoral studies in Neuro-virology and Cancer Biology from Temple University, Philadelphia. He is a Professor in Medical Science department of Rangsit University. Most of his publications concern viral diseases and immunity in invertebrates, inducible viral receptors and phage therapy.
Acinetobacter baumannii (AB) is one of the important multiple drug resistant (MDR) bacterial infection with environmental contamination especially in hospitals. AB is the major fatal cause of acquired hospital bacterial infection. With the limitation to develop new antibiotic drug, nowadays, phage therapy is reignited as an alternative strategy to fight against MDR bacterium. One of the main problems concerning phage therapy is that bacterium can develop to be a lysogen which becomes resistant to the same phage treatment. This lysogenic mechanism is regulated when bacterium host is infected by temperate phage which unfortunately seems to be the major kind of isolated phages by various researchers. It is seldom to isolate virulent phage which can keep re-infecting the bacterial host by the phage’s progeny without lysogenic pathway. Using the proper amounts of temperate phage, so called multiplicity of infection (MOI), to infect the bacterial hosts can theoretically prevent lysogenic pathway. However, it is not practical to perfectly prepare the proper amount of MOI for the treatment. In this study, many isolated ABs have been obtained from patients. The AB 116 and AB 160 are used as the models to study their susceptibility to phage therapy. Plural kinds of AB-phages (bacteriophages of AB) for each particular AB have also been isolated and called AB-phage a, b, c and d. AB-phage a and c can infect AB 116 while AB 160 can be infected by AB-phage a, b and d. In this presentation, using plural AB-phage to treat AB in vitro will be presented and discussed.
American Chemical Society, USA
Time : 11:20-12:05
Pillhun Son has earned his PhD from Texas Tech University in Organic and Computational Chemistry and then moved on to work on Material Science and Physical Chemistry during his Post-doctorate. He has worked on several database building and information solution initiatives for CAS, including, CASREACT (CAS’s premier reaction database) and the all new formulations information solution (set to launch mid 2017). Most recently, he has also achieved a MS in Information Systems from Northwestern University.
CAS is developing an information solution exclusively to support formulations work. The simple user interface taps into an all new content database of formulations extracted from patents, journals and other literature types. These formulations have been curated and analyzed by humans and then heavily indexed for easy exploration. The complex relationships and functions of substances within formulations have been captured as well as characteristics, physical form, application technique, manufacturing process and experimental results of the formulations themselves. By exploring the components and characteristics of formulations, a vivid understanding of the marketplace can be obtained then refined to the specific information of interest. Trend analysis will be applied to excipient information to extract further insights on how formulations have been constructed over time and geography for various purposes and targets.